Interstitial transfer factor as adjuvant immunotherapy for experimental glioma

Area of Science:

• Immunotherapy
• Oncology
• Cell Biology

Background:

• Glioblastoma multiforme (GBM) is an aggressive central nervous system tumor with poor prognosis.
• Effective therapies for GBM are limited, highlighting the need for novel treatment strategies.
• Immunotherapy, particularly using transfer factors (TF), presents a potential therapeutic avenue.

Purpose of the Study:

• To evaluate the efficacy of transfer factors (TF) as an immunotherapy for experimental glioblastoma.
• To determine optimal dosing and assess combination therapy with carmustine.

Main Methods:

• TF derived from immunized swine were administered intratumorally at varying doses.
• Experimental therapy involved combining the optimal TF dose with carmustine in rats with C6 glioma.
• Immune cell populations (CD2+, CD4+, CD8+, NK) were analyzed via flow cytometry.
• Tumor cytokine expression (RT-PCR) and apoptosis (sub-G0 method) were assessed.

Main Results:

• Intratumoral TF significantly reduced glioblastoma tumor size.
• TF administration increased peripheral blood T lymphocyte and NK cell counts.
• TF therapy enhanced tumor cell apoptosis and increased Th1 cytokine expression in tumor tissue.
• Combining TF with carmustine demonstrated an additive anti-tumor effect.

Conclusions:

• Transfer factors (TF) exhibit significant anti-tumor activity against experimental glioblastoma.
• TF immunotherapy modulates immune cell populations and promotes tumor apoptosis.
• TF combined with chemotherapy offers an additive therapeutic benefit for glioblastoma treatment.